BIT
AIMT

BlackRock Institutional Trust’s Aimmune Therapeutics AIMT Stock Holding History

BlackRock Institutional Trust’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$13.1M Buy
638,472
+328,750
+106% +$6.72M ﹤0.01% 2243
2016
Q3 		$4.65M Buy
309,722
+52,213
+20% +$705K ﹤0.01% 2723
2016
Q2 		$2.79M Buy
257,509
+140,908
+121% +$1.91M ﹤0.01% 2920
2016
Q1 		$1.58M Sell
116,601
-2,694
-2% -$42K ﹤0.01% 3138
2015
Q4 		$2.2M Buy
119,295
+15,380
+15% +$285K ﹤0.01% 3080
2015
Q3 		$2.63M Buy
+103,915
New +$2.43M ﹤0.01% 3012

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BlackRock Institutional Trust's AIMT Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Aimmune Therapeutics (AIMT) stake by 106% in Q4 2016, buying an estimated $6.72M and bringing the position to 638,472 shares worth $13.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2243.

BlackRock Institutional Trust first reported a position in AIMT in Q3 2015 and has held it in 6 quarters since. 92 funds tracked by Wall St. Rank hold AIMT as of Q4 2016.

  • BlackRock Institutional Trust held 638,472 shares of Aimmune Therapeutics worth $13.1M as of Q4 2016.
  • BlackRock Institutional Trust bought 328,750 Aimmune Therapeutics shares in Q4 2016, an estimated $6.72M.
  • Aimmune Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #2243 holding.
  • BlackRock Institutional Trust first reported a position in Aimmune Therapeutics in Q3 2015 and has held it in 6 quarters since.
  • 92 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.